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Establishing a blueprint for CED-3-dependent killing through
identification of multiple substrates for this protease
Abstract
Genetic studies have established that the cysteine protease CED-3 plays a central role in coordinating
programmed cell death in Caenorhabditis elegans. However, it remains unclear how CED-3 activation
results in cell death because few substrates for this protease have been described. We have used a global
proteomics approach to seek substrates for CED-3 and have identified 22 worm proteins that undergo
CED-3-dependent proteolysis. Proteins that were found to be substrates for CED-3 included the
cytoskeleton proteins actin, myosin light chain, and tubulin, as well as proteins involved in ATP
synthesis, cellular metabolism, and chaperone function. We estimate that approximately 3% of the C.
elegans proteome is susceptible to CED-3-dependent proteolysis. Notably, the endoplasmic reticulum
chaperone calreticulin, which has been implicated in the recognition of apoptotic cells by phagocytes,
was cleaved by CED-3 and was also cleaved by human caspases during apoptosis. Inhibitors of caspase
activity blocked the appearance of calreticulin on the surface of apoptotic cells, suggesting a mechanism
for the surface display of calreticulin during apoptosis. Further analysis of these substrates is likely to
yield important insights into the mechanism of killing by CED-3 and its human caspase counterparts.
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Genetic studies have established that the
cysteine protease CED-3 plays a central role in
coordinating programmed cell death in C.
elegans.  However, it remains unclear how
CED-3 activation results in cell death as few
substrates for this protease have been
described.  We have used a global proteomics
approach to seek substrates for CED-3 and
have identified 22 worm proteins that undergo
CED-3-dependent proteolysis.  Proteins that
were found to be substrates for CED-3 included
the cytoskeleton proteins actin, myosin light
chain and tubulin, as well as proteins involved
in ATP synthesis, cellular metabolism and
chaperone function. We estimate that
approximately 3 % of the C. elegans proteome
is susceptible to CED-3-dependent proteolysis.
Notably, the ER chaperone calreticulin, which
has been implicated in the recognition of
apoptotic cells by phagocytes, was cleaved by
CED-3 and was also cleaved by human caspases
during apoptosis.  Inhibitors of caspase activity
blocked the appearance of calreticulin on the
surface of apoptotic cells, suggesting a
mechanism for the surface display of
calreticulin during apoptosis.  Further analysis
of these substrates is likely to yield important
insights into the mechanism of killing by CED-3
and its human caspase counterparts.
INTRODUCTION
The caspase family of cysteine proteases have
been implicated in the regulation of programmed
cell death in numerous organisms, from simple
invertebrates to man (1).  Caspases are present in
most cells as inactive proenzymes and become
activated during apoptosis through diverse
signalling pathways (2,3).  Upon activation,
caspases promote programmed cell death by
restricted proteolysis of numerous proteins within
the dying cell (4). Caspase-dependent proteolytic
events produce dramatic rearrangements of the
cellular architecture and engulfment of the dying
cell by phagocytes (5).
The nematode C. elegans has contributed
greatly to our understanding of the regulation of
cell death in metazoans through discovery of a
series of cell death defective (ced) genes (6,7).  In
several cases, this led directly to the discovery of a
role for their mammalian counterparts in the
regulation of apoptosis, the caspases being a
notable example (8-10).  The worm caspase, CED-
3, has been established as essential for the great
majority of developmental-related programmed
cell deaths in the worm (6,11).  Similar to
mammalian caspases, CED-3 is probably present
in most cells as an inactive precursor but becomes
activated in cells fated to die during development.
CED-3 activation is achieved through recruitment
of the inactive CED-3 precursor to the scaffold
protein CED-4, which assembles into a tetrameric
complex (12).  The latter event is normally
prevented by CED-9, which represses CED-4
tetramerization and CED-3 recruitment (12,13).
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2However, while CED-3 is firmly established as a
central participant in the molecular control of
programmed cell death in the worm, how
activation of this protease results in cell death is
obscure as few substrates for CED-3 have been
identified thus far.  Understanding how CED-3
kills cells in the worm is of considerable interest,
not only because this is likely to shed further light
upon how programmed cell death is coordinated in
this organism, but this is also likely to generate
insight into how human caspases promote
apoptosis.  The observation that a single caspase is
sufficient to coordinate apoptosis in the worm
suggests that CED-3 harbors all of the activities
that have subsequently become allocated to several
different caspases in higher organisms.
Here we have used two-dimensional gel-based
proteomics to seek substrates for CED-3.  This
approach yielded 22 substrates and included
proteins involved in protein and DNA synthesis,
chaperone function, cellular metabolism and the
cytoskeleton.  We estimate that approximately 3%
of the worm proteome is susceptible to CED-3-
dependent proteolysis.  These data suggest that
CED-3 promotes cell  death through
simultaneously targeting diverse cellular
functions.  Detailed analysis of these substrates is
likely to yield important insights into the
mechanism of killing by CED-3.
EXPERIMENTAL PROCEDURES
Reagents–The following antibodies were used
for immunoblotting: anti-CED-3 C-20 (Santa
Cruz, UK), anti-GST (BD Pharmingen, UK), anti-
beta tubulin (ICN, UK), anti-calreticulin
polyclonal antibody (Affinity Bioreagents, USA)
and anti-calreticulin monoclonal antibody
(Transduction Laboratories, UK).  Anti-
calreticulin polyclonal antibody was also used for
surface immunostaining in conjunction with anti-
rabbit-Alexafluor 488 as a secondary antibody
(Molecular Probes, UK).  Rabbit polyclonal
antibodies were generated against recombinant
CED-3, as follows.  Briefly, His-CED-3221-503 was
expressed in E. coli, purified over Ni-NTA
agarose and rabbits immunized with the purified
protein.  Polyclonal antibodies against p17 and
p13 domain peptides of CED-3 were also
generated and affinity purified using the
immunization peptides.  The peptides z-VAD-fmk,
Ac-DEVD-AFC, Ac-LEHD-AFC, Ac-IETD-AFC
and Ac-YVAD-AFC were purchased from
Bachem (UK).  17 cm IPG strips (pH 3-6 and pH
5-8), easymelt agarose and Bio-Lyte ampholytesTM
were obtained from Biorad (UK).  The serine
p r o t e a s e  i n h i b i t o r s ,
tosylphenylalanylchloromethane (TPCK) and 3,4-
dichloroisocoumarin (DCI) were purchased from
Merck (UK).  Unless otherwise indicated, all other
reagents were purchased from Sigma (Ireland)
Ltd.
Plasmids and site-directed mutagenesis–The
CED-3221-503 ORF was cloned from a pQE30-
CED-3221-503 template (kindly provided by Dr. Shai
Shaham) into the pGEX4TK2 vector to generate
GST-tagged CED-33221-503.  Crt-1, Tbb-2 and Ftt-2
ORFs were amplified by PCR from a C. elegans
cDNA library (Origene) and cloned into the
pET45b vector.  The human calreticulin ORF was
amplified by PCR from an IMAGE clone (MRC,
UK) and inserted into pcDNA3.  Site-directed
mutagenesis was carried out using the
Quickchange kit (Stratagene).  All plasmids were
verified by DNA sequencing.
Expression and purification of recombinant
CED-3–E. coli DH5α cells were transformed with
pGEX4TK2-CED-3221-503.   CED-3 protein
expression was induced by addition of 100 µM
IPTG to culture media followed by a 3 hour
incubation at 25oC.  Proteins were affinity purified
on glutathione sepharose, as previously described,
and eluted in protease reaction buffer (PRB; 50
mM HEPES, pH7.4, 75 mM NaC1, 0.1 %
CHAPS, 2 mM DTT) with 10 mM glutathione.
CED-3 was then active site titrated against
AcDEVD-AFC, using zVAD-fmk as an
inhibitor.
Fluorimetry assays–Reactions containing
recombinant GST-CED-3221-503 were typically
assembled in a final volume of 100 µl, containing
50 µM Ac-DEVD-AFC, Ac-LEHD-AFC, Ac-
IETD-AFC, or Ac-YVAD-AFC in PRB.
Fluorescence was then measured in an automated
fluorimeter (Spectrafluor Plus, TECAN, UK) at
wavelengths of 430 nm (excitation) and 535 nm
(emission).
Coupled in vitro transcription/ translation–35S-
methionine-labeled proteins were generated using
the TNT kit (Promega) as described previously
(Martin et al., 1996).  Typically, 25 µl reactions
were assembled containing 0.5 µg of template
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3plasmid DNA and 2 µl of translation grade 35S-
methionine (1000 mCi/ ml, MP Biomedicals, UK).
Nematode cell-free reactions–Bristol N2 strain
C. elegans were harvested from a 250 ml liquid
culture by centrifugation at 500 g for 5 mins.
Nematodes were washed twice in 50 ml of 100
mM NaCl, added to 20 ml of 60 % sucrose and
centrifuged for 5 mins at 5000 g. Worms
were immediately removed from the
sucrose and washed in 100 mM NaCl.
Following a final centrifugation at 500 g,
pelleted worms were resuspended in 2 volumes of
extract buffer (20 mM HEPES-KOH, pH7.5, 10
mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM
EGTA, 1 mM DTT, 100 µM PMSF, 10 µg/ml
leupeptin, 2 µg/ml aprotonin).  Resuspended
worms were lysed by sonication and insoluble
material was pelleted for 15 mins at 15,000 g.
CED-3 was added to soluble C. elegans extract at
130 nM (as determined by active site titration with
z-VAD-fmk) unless  otherwise indicated.
Reactions were incubated for 2 h at 37 oC to
facilitate CED-3-dependent proteolysis.  Cell free
reactions were then assessed by immunoblotting or
subjected to two-dimensional electrophoresis as
described.
T w o - d i m e n s i o n a l  e l e c t r o p h o r e s i s –
Approximately 500 µg of protein was solubilized
to a final volume of 350 µl in IEF sample buffer (8
M Urea, 4 % CHAPS, 0.05 % SDS, 100 mM DTT,
0.2 % w/v Bio-Lyte ampholytesTM, 0.02 % w/v
Bromophenol blue).  IPG strips were passively
rehydrated in the presence of protein samples
overnight.  Samples were then focused on a Biorad
IEF cell under the following conditions: (1) a
linear voltage ramp to 500 V over 1 h, (2) 5 h at a
constant 500 V to facilitate desalting, (3) linear
voltage ramp to 3500V over 5 h and (4) 15 h at a
constant 3500 V.  Following isoelectric focusing,
IPG strips were prepared for second dimension
SDS-PAGE by a 10 min incubation in reducing
buffer (2 % w/v DTT in 6 M Urea, 375 mM Tris
HCl, pH 8.8, 2 % SDS, 20 % Glycerol), followed
by a 10 min incubation in alkylating buffer (2.5 %
w/v iodoacetimide in 6 M Urea, 375 mM Tris
HCl, pH 8.8, 2 % SDS, 20 % Glycerol).  Strips
were then mounted on 12 % SDS-PAGE gels
using 1-2 ml of easymelt agarose (Biorad, UK)
and electrophoresed at 37.5 mA per gel in a Biorad
Protean IIxi electrophoresis cell (Biorad, UK).
Silver Staining of two-dimensional
gels–Proteins were visualized using a Mass
Spectrometry-compatible silver staining protocol
as previously described (14).  Silver-stained gel
images were acquired using a digital camera and
were visually inspected for CED-3-dependent
changes in spot patterns.
In-gel protein digestion and identification by
MALDI-TOF mass-spectrometry–Candidate
protein spots were excised from 2-D gels, in-gel
digested with trypsin, extracted, and identified by
MALDI-TOF mass spectrometry (ABI Voyager
DE-Pro), as previously described (14).
Cell culture and induction of apoptosis–CEM
cells were cultured in RPMI 1640/ 10 % fetal calf
serum under standard conditions.  Apoptosis was
induced by incubation in indicated concentrations
of actinomycin D, TPCK or DCI.  To quantitate
apoptosis, cells were stained with annexin V-FITC
at 1 µg/ml and propidium iodide at 10 µg/ml in
annexin V binding buffer (10 mM Hepes-NaOH,
pH 7.4, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2,
1.8 mM CaCl2).  Cell fluorescence was measured
on a flow cytometer (FACSCalibur, Becton
Dickinson, CA).
Immunostaining–Cells were washed with PBS
containing 3 % BSA and 0.05 % NaN3, followed
by a 15 minute incubation in the same buffer.
Antibodies were added at 1:400 and incubated for
1 hour.  After a further three washes, secondary
antibody was added at 1:500 for 1 hour.  Cells
were washed another three times and fixed for 15
minutes in PBS/ 3% PFA, then prepared for flow
cytometry.
Preparation of Cell Lysates–Cells were
pelleted at 800 g and resuspended at 2 x 107 cells/
ml in SDS-PAGE loading buffer (2 % SDS, 50
mM Tris-HCI, pH 6.8, 10% glycerol, 2.5 % β-
mercaptoethanol).  Lysates were assessed by
immunoblotting.
Preparation and activation of Jurkat cell-free
extracts–Cell-free extracts were prepared from
human Jurkat cells and caspases were activated by
addition of cytochrome c and dATP to these
extracts, as described previously (14,15).
RESULTS
CED-3 displays characteristics of initiator and
effector caspases–Programmed cell death in the
nematode takes place in scattered cells during
development such that out of a total of 1090 cells
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4born in the C. elegans hermaphrodite, 131 of these
die in a programmed manner (16).  Preliminary
studies established that it was not possible to
induce coordinate programmed cell death in worm
embryos or in the somatic cells of adult worms
using UV radiation, microtubule-disrupting drugs,
or inhibitors of protein or RNA synthesis (RT and
SJM; data not shown).  The latter stimuli readily
trigger apoptosis in fly and mammalian cells and
their failure to do so in the worm suggests that a
damage-associated programmed cell death
pathway is absent in the majority of somatic cells
in the nematode.  Because it was not possible to
obtain homogenous populations of dying cells
from worm embryos or larval stages, we adopted a
biochemical approach to finding CED-3
substrates.  This involved generating homogenates
from mixed-stage worm populations to which
recombinant active CED-3 was added.
To obtain recombinant CED-3 we generated a
variety of expression constructs including; full
length CED-3, a truncated CED-3 lacking the N-
terminal prodomain, and constructs encoding the
large and small subunits individually.  However,
most of these failed to produce soluble protein and
several denaturation and re-folding strategies
proved unsuccessful (data not shown).
Recombinant active CED-3 was produced by
removing the N-terminal CARD domain of the
protease (aa 1-220), and replacing with glutathione
S-transferase (GST; Figure 1A and B).  Purified
GST-CED-3 fusion protein exhibited robust
proteolytic activity against several synthetic
caspase substrate peptides including DEVD-AFC,
IETD-AFC and LEHD-AFC (Figure 1C).  In
contrast, CED-3 did not hydrolyze YVAD-AFC, a
substrate that is commonly preferred by
inflammatory caspases in mammals.  CED-3
exhibited a preference for DEVD-AFC, which is
typical of mammalian effector caspases such as
caspase-3, but was also capable of cleaving IETD-
AFC and LEHD-AFC relatively efficiently (Figure
1C).  Importantly, an N-terminally His-tagged
CED-3 construct also displayed similar activity
towards tetrapeptide substrates (Supplemental
Figure S1), suggesting that addition of the N-
terminal GST moiety did not significantly alter the
specificity of CED-3 towards peptide substrates.
Thus, CED-3 appears to be more promiscuous
than the major effector caspase in mammals
(caspase-3), which is consistent with the role of
CED-3 as the only essential effector, as well as
initiator, caspase in the worm.
We also assessed the catalytic activity of
recombinant CED-3 using protein substrates that
were produced by coupled in vitro
transcription/translation.  CED-3 has previously
been reported to cleave its own precursor,
consistent with its ability to autoactivate (17).
Moreover, CED-3 is also reported to cleave the
cell death inhibitor CED-9 in vitro (18).
Therefore, we titrated recombinant GST-CED-3
onto 35S-labeled pro-CED-3 and 35S-labeled CED-
9 to assess the ability of CED-3 to cleave these
proteins (Figure 1D).  As Figure 1D illustrates,
CED-3 cleaved its own precursor to fragments of
~17 kDa and ~13 kDa consistent with separation
of the large and small subunits through proteolysis
at Asp374 and Asp388.  However, addition of C.
elegans homogenate (see below) significantly
attenuated the activity of GST-CED-3 towards
both 35S-labeled substrates (Figure 1D and
Supplemental Figure S2).  CED-3-mediated
proteolysis of pro-CED-3 and CED-9 was also
largely suppressed by the poly-caspase inhibitor,
z-VAD-fmk (Figure 1E).
CED-3-dependent proteolysis in C. elegans
homogenates–To screen for CED-3 substrates
within the C. elegans proteome, we generated
worm homogenates as follows.  Mixed-stage
populations of C. elegans were grown in liquid
cultures until bacteria were entirely cleared as this
facilitated the elimination of contaminating E. coli
from the worm digestive tracts.  Worms were then
washed several times in M9 buffer followed by
purification over sucrose gradients.  Homogenates
of worm populations were generated by brief
sonication and the resulting protein preparations
were clarified by centrifugation at 15,000 g to
eliminate unbroken worms and empty cuticles
(Supplemental Figure S3).  These preparations
were then incubated for 2 h at 37 oC in the
presence or absence of recombinant CED-3.  The
concentration of CED-3 chosen was based upon
preliminary titrations of recombinant CED-3
against known substrates, in the presence and
absence of worm homogenates (as shown in
Figure 1D).  Proteins were separated by one-
dimensional SDS-PAGE.  As shown in Figure 2A,
incubation of C. elegans homogenates with active
GST-CED-3 failed to reveal any obvious
alterations to the worm proteome suggesting that
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5CED-3 is a highly specific protease that cleaves
relatively few substrate proteins, at least at
concentrations where this protease can process its
own precursor (Figure 1D).
We next analysed similar CED-3-treated worm
homogenates using two-dimensional (2D) SDS-
PAGE and these analyses were successful in
detecting ~ 40 alterations to the 2D protein spot
patterns (Figures 2B and 2C, Supplemental Figure
S4).  Altered protein spots were then excised from
the gels and proteins were identified by MALDI-
TOF mass spectrometry.  As illustrated in Figure
3A and Supplemental Table I, 22 proteins were
identified as undergoing CED-3-dependent
proteolysis under these conditions.  These
included proteins involved in a diverse range of
cellular functions.  Of note, several homologues of
known human caspase substrates were identified,
including the cytoskeletal proteins actin, myosin
and α-tubulin (19,20); a 14-3-3 protein (21); and a
nucleosome assembly protein-1 homologue (22).
Additionally, several of the substrates identified,
including actin, myosin, tubulin, and calreticulin
have previously been implicated in apoptosis-
associated events in mammalian systems (20,23-
25).
Validation of CED-3 substrates–To confirm
that the identifed proteins were bona fide CED-3
substrates rather than 2D-PAGE running artifacts,
we cloned several of the genes encoding these
proteins and explored whether in vitro transcribed
and translated forms of these proteins were
cleaved by CED-3 in vitro.  As Figure 3B-D
illustrates, 14-3-3 family protein 2 (FTT-2),
calreticulin (CRT-1), and tubulin beta 2 (TBB-2)
were cleaved by CED-3 with comparable
efficiency to the known substrates pro-CED-3 and
CED-9.   In contrast, a panel of control worm
proteins failed to undergo substantial proteolysis
under the same conditions (Supplemental Figure
S5).
Sites of CED-3-mediated cleavage in FTT-2,
CRT-1 and TBB-2 were mapped by site-directed
mutagenesis as shown in Figure 3B-D.  In the case
of FTT-2, a single CED-3 cleavage site (Asp240)
appeared to be responsible for the proteolysis seen,
as mutation of this site completely suppressed
FTT-2 cleavage by CED-3 (Figure 3B).  In the
case of TBB-2, mutation of three potential sites
individually caused changes in the pattern of
substrate proteolysis (data not shown) while
mutation of all three sites simultaneously resulted
in only a partial reduction in substrate cleavage
efficiency, suggesting that multiple CED-3
cleavage sites are present in TBB-2 (Figure 3C).
A similar situation prevailed in the case of CRT-1,
although mutation of three candidate sites in this
protein did substantially attenuate proteolysis by
CED-3 (Figure 3D).  The majority of the sites
found in these substrates were found to match the
consensus DXXD (Table I), which is also typical
of mammalian effector caspases.  In addition,
where multiple cleavage sites existed within a
particular substrate, sites matching the DXXD
consensus were the most efficiently cleaved (data
not shown).
Cleavage of human homologues–While it was
not possible due to the lack of suitable antibodies
to explore whether all CED-3 substrate
homologues were also caspase substrates in man,
we were able to confirm this in the case of FTT-2
homologues 14-3-3 β , ε and τ, TBB-2 homologue
β -tubulin isoform 5, and CRT-1 homologue
calreticulin.  As shown in Figure 4A, three human
14-3-3 isoforms underwent caspase-mediated
proteolysis in a human cell-free system based on
Jurkat cell-free extracts, while a fourth isoform,
14-3-3 ζ, remained uncleaved (data not shown).
Human β -tubulin and calreticulin were also
confirmed to be caspase substrates in apoptotic
cell extracts (Figure 4B and C).
Calreticulin is cleaved during apoptosis and
exposed on the surface of apoptotic cells–The
identification of the ER chaperone calreticulin as a
caspase substrate was particularly interesting, as a
recent report has shown that calreticulin is
exposed on the cell surface during apoptosis (25).
Cell surface-exposed calreticulin acts as a ligand
for CD91 on phagocytes, leading to engulfment of
the apoptotic cell (25).  Thus, calreticulin appears
to act as an inducible engulfment signal, the
appearance of which on the cell surface may be
controlled by caspases.  To explore this
possibility, we first assessed whether cleavage of
calreticulin occured in human CEM cells after
exposure to a range of pro-apoptotic stimuli
(actinomycin D, TPCK and DCI).  Proteolysis of
calreticulin was indeed observed during apoptosis,
although a relatively small proportion of the total
cellular protein appeared to be cleaved in
comparison to substrates such as XIAP and
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6caspase-9 (Figure 4D). Because the majority of
calreticulin in healthy cells is contained within the
ER, this protein is largely inacessible to caspases,
which may explain the inefficient proteolysis seen
during apoptosis.  In contrast, when in vitro
transcribed and translated calreticulin was added
to cell-free extracts, where this protein was not
protected by ER, very robust proteolysis of
calreticulin was observed (Figure 4C).
We then explored whether surface exposure of
calreticulin during apoptosis could be detected by
immunostaining with an anti-calreticulin antibody,
as recently reported (25).  As Figure 5A illustrates,
whereas healthy CEM cells exhibited little surface
immunoreactivity for calreticulin (Crt), this
changed dramatically upon exposure to Act D,
DCI or etoposide (VP-16), all of which promoted
robust apoptosis under these conditions.
Significantly, when these cells were treated with
the caspase inhibitor z-VAD-fmk, surface
exposure of calreticulin was profoundly inhibited
(Figure 5B).  In addition, CEM cells stably
expressing the apoptosis-inhibitory protein Bcl-2
also failed to exhibit an increase in surface
calreticulin upon exposure to Act D (Figure 5C).
In contrast, surface expression of calreticulin was
readily detected in wild type CEM cells under the
same conditions (Figure 5C).  Thus, caspase
activity appears to be essential for the cell surface
exposure of calreticulin during apoptosis.
DISCUSSION
In this study, we have identified 22 novel
substrates of the C. elegans caspase CED-3.  As
only four CED-3 substrates have been identified to
date (17,18,26) the present study represents a
significant advance in our understanding of how
CED-3 coordinates cell death.  The substrates
identified herein may be enriched in proteins that
play important roles during CED-3-dependent cell
death in the worm.  Further analysis of the roles of
these substrates may also yield novel insights into
the execution phase of apoptosis in multiple
organisms.
It is important to note that the approach we
have used to identify CED-3 substrates has several
potential drawbacks.  First, due to the use of worm
homogenates in our study, compartmentalization
of many proteins will have been disrupted and this
may render such proteins more accessible to CED-
3-mediated proteolysis than in intact cells.
Second, we have used recombinant GST-CED-3 at
concentrations that may well be significantly
higher (or lower) than in worm cells undergoing
programmed cell death.  Due to the lack of
suitable antibodies to measure this, the
concentration of CED-3 expressed in worm cells
undergoing PCD remains unknown.   Third, the
use of 2D gels restricted us to visualizing only the
most abundant proteins within the worm
proteome.  Thus, there is a high probability that
numerous additional C. elegans proteins, of
relatively low abundance, are also subjected to
proteolysis by CED-3 during cell death.
These caveats beg the question of why we
pursued the biochemical approach adopted in this
study, as opposed to analyzing CED-3-dependent
proteolysis in dying worm cells for example?  The
answer to this is very straightforward.  Due to the
very small percentages (~12%) of cells undergoing
developmental PCD in the worm, coupled with the
fact that such cell deaths are asynchronous, it was
technically unfeasible to detect CED-3-dependent
changes to the worm proteome using intact worms
or embryos (data not shown).  Furthermore, as
noted in the Results section, numerous attempts to
induce coordinate cell death in worm embryos or
adults  (using UV radiat ion,  cancer
chemotherapeutic drugs, protein and RNA
synthesis inhibitors and heat-shock) were
unsuccessful (RT and SJM, data not shown).
Indeed, it is likely that the combination of these
factors have contributed to the remarkable paucity
of knowledge concerning the mechanism of action
of CED-3 during worm PCD.
CED-3 plays a dual role in worm PCD, acting
as an initiator as well as an executioner caspase in
this organism.  We also explored the relationship
of CED-3 to human caspase-3 in terms of substrate
specificity.  Using fluorogenic peptide substrates,
CED-3 exhibited a clear preference for DEVD-
AFC, reflecting its close relationship to the human
executioner caspase-3.  Indeed, the closest
sequence homologues of CED-3 in humans are the
executioner caspases caspase-3 and caspase-7.
However, CED-3 exhibited a higher degree of
promiscuity in its ability to hydrolyse the
substrates IETD-AFC and LEHD-AFC, reflecting
its broader role in C. elegans PCD.  This
preference was reflected in the CED-3 cleavage
sites identified in protein substrates (Table I).  7
out of 12 known CED-3 cleavage sites match a
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7DXXD consensus.  Amongst the other sites, the P4
aspartate was substituted for glutamic acid (2
sites), asparagine (2 sites) or valine (1 site).
Where multiple sites were present, DXXD sites
were the most readily cleaved (data not shown).
Interestingly, the P1' site was in all but one case
occupied by a small amino acid, suggesting that
CED-3 cleavage site specificity may extend
further than the traditional tetrapeptide motif, as
suggested for several of the human caspases (27).
During the execution phase of apoptosis, cells
undergo a stereotypical set of morphological
changes including detachment and rounding,
membrane blebbing, fragmentation of chromatin
and cellular organelles, formation of apoptotic
bodies, and the exposure of “eat-me” signals for
phagocytes.  In keeping with this, proteins targeted
by CED-3 are involved in diverse cellular
functions.  Notably, several are components of the
cytoskeleton, and these substrates already have
known roles in apoptosis-associated events.  Actin
and myosin are thought to provide the contractile
force for cell blebbing and fragmentation
(23,24,28), while changes in microtubules may act
to transport fragmented chromatin or phagocytic
effectors into late stage blebs (29).  As removal of
the C-terminus of human α-tubulin by the serine
protease granzyme B results in increased rates of
polymerization (20), it may be that removal of
tubulin C-termini by proteases is a common
mechanism of functional disruption of
microtubules during apoptosis.
Changes in apoptotic cells require energy and
during early stages of apoptosis ATP-generation
systems remain unperturbed.  However, later
stages of apoptosis are characterized by a
shutdown of energy production, and cleavage of
ATP synthase subunits may contribute to this.
Interestingly, the vacuolar ATP synthase of which
VBA-13 is a subunit has been recently implicated
in generating the acidic conditions required for
neurodegeneration (30).  This suggests that
disabling the vacuolar ATPase may prevent dying
cells from undergoing necrosis before completion
of the PCD pathway.  In addition, many substrates
identified here are involved in cellular
metabolism.  This may reflect a general shutdown
of energy-consuming processes in apoptotic cells.
It may also help to ensure the irreversibility of the
apoptotic process, as cells are unable to survive
once essential processes are shut down.  However,
the abundance of metabolic proteins identified in
this analysis is possibly due to the proteomics
technology used as 2D electrophoresis reveals the
most abundant proteins within the proteome,
among which proteins with metabolic functions
are over-represented.
Other cleavage events may function to disable
cell survival pathways.  14-3-3 proteins such as
FTT-2 play roles in several survival pathways, and
have already been identified as substrates of
human caspases (21).  Chaperone proteins may
also be targeted during apoptosis to prevent futile
attempts to prolong survival.  Interestingly, the
chaperone substrate calreticulin is required for
necrosis in C. elegans (31).  Recent studies also
suggests that calreticulin is exposed on the cell
surface during apoptosis and acts as a signal
allowing phagocyte attachment and cell
engulfment (25,32).  Furthermore, caspase-
dependent exposure of calreticulin in response to
certain pro-apoptotic stimuli appears to influence
the immunogenicity of tumors (32).  Thus, dying
cells with elevated levels of surface calreticulin
provoked strong immune-mediated clearance
which may be related to the efficiency of uptake of
the latter cells by dentritic cells (32).  Here we
have provided evidence that cleavage of
calreticulin by caspases influences its surface
exposure by a mechanism that remains to be
defined.
Another intriguing observation was the
identification of two aspartic proteases as CED-3
substrates. This raises the possibility that a
protease activation cascade exists in the worm,
involving aspartic as well as caspase proteases.  In
mammalian systems, it has frequently been
suggested that proteases other than caspases may
play a role in cell death.  This leaves open the
possibility that some of the proteins altered in our
analysis may in fact be targets of these other
proteases, and are therefore indirect results of
CED-3 activation.  Alternatively, because these
aspartic proteases are related to proteases
implicated in necrotic cell death in C. elegans
(33), cleavage by CED-3 might inactivate such
proteases to ensure that cells undergoing PCD do
not manifest necrotic changes.  The observation
that 4 of the 22 substrates identified here are
potentially required for necrosis in C. elegans may
reflect a general strategy to prevent diversion of
apoptotic cells into necrosis.
 at H
auptbibliothek Universitaet Zuerich Irchel. Bereich Forschung, on February 8, 2010
w
w
w
.jbc.org
D
ow
nloaded from
 
8While few substrates for CED-3 have
previously been described, almost 400 substrates
for the mammalian caspases have now been
identified (34).  However, the vast majority of
these substrates have been identified, at random,
over a period of 10 years or so.  Few systematic
searches for caspase substrates, similar to the one
reported here, have been conducted to date.  One
recent study used a non-gel chromatographic-
based approach, coupled with mass spectrometry,
to search for human caspase substrates in Jurkat
cells undergoing apoptosis in response to CD95
receptor ligation (22).  This approach yielded 92
putative caspase substrates, some of which were
validated as bona fide substrates for these
proteases.  The latter study adopted a novel and
sensitive method for the detection of newly-
generated protein N-termini (22).  However, even
with sophisticated methods such as those
employed by Van Damme et al., (22), it is clear
that proteomics-based screening approaches do not
completely cover the proteome, as several hundred
known caspase substrates were not detected by
this approach (34).  Clearly, several factors can
influence the likelihood of detecting proteolysis of
particular proteins, including: the source of the
tissue used for the analysis (which will have an
impact on the relative abundance of particular
proteins), the analytical method employed (e.g.
some proteins resolve very poorly on 2D gels due
to size and charge issues, some peptides do not fly
well in mass spectrometers), the efficiency of
proteolysis of particular substrates, and other
factors.  Because of the above considerations, it is
highly likely that many more substrates for CED-3
will be found by using complementary
approaches.
In summary, this study provides the first
detailed analysis of the proteins that undergo
CED-3-dependent proteolysis in the nematode C.
elegans and reveals that CED-3 targets a relatively
restricted set of proteins to coordinate cell death,
many of which are conserved caspase substrates in
mammals.
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FIGURE LEGENDS
Figure 1.  Proteolytic activity of purified GST-CED-3
(A) Schematic showing predicted products of GST-CED-3221-503 autoproteolysis.
(B) GST-tagged CED-3221-503 was expressed in E. coli and purified from bacterial lysates.  Purified
protein was electrophoresed through 12 % SDS-PAGE gels and either stained with Coomassie Blue or
subjected to Western blotting with antibodies specific to GST and the p17 and p13 subunits of CED-3.
Purified GST alone and purified recombinant His6-tagged CED-3221-503 were also loaded as controls.
Bands are labeled according to the scheme shown in (A).
(C) Purified GST-CED-3221-503 and human caspase 3 were assayed for their ability to support hydrolysis
of the fluorogenic caspase substrate peptides ac-DEVD-AFC, ac-IETD-AFC, ac-LEHD-AFC and ac-
YVAD-AFC.
(D) A range of concentrations of GST-CED-3221-503 were added to 35S-Met-labelled CED-3 and CED-9
with or without C. elegans mixed stage cell-free extract (CFE).  Ratios shown represent dilutions of the
CED-3 protease stock.  The stock concentration of CED-3 was 400 nM, therefore the concentrations used
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10
were 200, 130, 100, and 80 nM.  Reactions were incubated for 2 hours at 37 °C followed by
electrophoresis on 12 % SDS-PAGE gels.
(E) 35S-Met-labelled CED-3 and CED-9 were incubated for 2 hours at 37 °C with 100 nM of GST-CED-
3221-503 and a range of concentrations of the caspase inhibitor z-VAD-fmk, followed by electrophoresis on
12% SDS-PAGE gels.
Figure 2.  Detection of CED-3-induced alterations in the C. elegans proteome
(A) Homogenates of mixed-stage C. elegans populations (CFE) were treated with recombinant GST-
CED-3 (130 nM final concentration) for 2 h at 37°C.  CED-3-treated homogenates were electrophoresed
alongside mock-treated lysates on one-dimensional 12% SDS-PAGE gels.  An equivalent amount of
CED-3 alone (i.e. without C. elegans CFE) was also loaded for comparison.  Proteins were visualized by
staining with Coomassie Blue.  The indicated proteins (arrows) represent abundant landmark proteins that
were identified by MALDI-TOF mass spectrometry.
(B) Protein samples (450 µg) from C. elegans homogenates mock-treated or incubated with CED-3 (130
nM final concentration) as above were subjected to isoelectric focusing on pI 5-8 IPG strips followed by
electrophoresis through 12 % second-dimension SDS-PAGE gels.  Proteins were visualized by silver
staining.  Protein spots disappearing upon treatment with CED-3 are circled; those appearing after CED-3
treatment are enclosed by squares.
(C) Enlarged regions of two-dimensional SDS-PAGE gels are shown.  Proteins reproducibly altered upon
CED-3 treatment, either disappearing or appearing upon treatment of homogenates with CED-3, are
indicated by circles.  The MALDI-TOF mass spectrograms used to identify these proteins are shown
alongside.  Other protein changes occurring in these panels are additional CED-3-mediated alterations
that have not been annotated here in order to focus upon individual changes.
Figure 3.  Identification and validation of candidate CED-3 substrates
(A) Proteins reproducibly altered upon treatment of C. elegans lysates with GST-CED-3 and identified by
MALDI-TOF mass spectrometry (see Supplemental Table 1 for full details).
(B-D) 35S-Methionine-labelled FTT-2 (B), CRT-1 (C) and TBB-2 (D) were incubated alongside pro-
CED-3 and CED-9 with a range of concentrations of GST-CED-3 for 2 h at 37 °C. Ratios shown
represent dilutions of the CED-3 protease stock.  The stock concentration of CED-3 was 400 nM,
therefore the concentrations used were 100, 50 and 25 nM.  Reaction products were resolved by SDS-
PAGE.  Cleavage site aspartates were then mutated to glutamates by site-directed mutagenesis.  Mutant
and wild-type proteins were incubated with GST-CED-3 at 200, 100, 50 and 25 nM, and subjected to
SDS-PAGE as above.  Schematic representations of substrate proteins are shown below with CED-3
cleavage sites indicated.
Figure 4.  Human homologs of CED-3 substrates are substrates for mammalian caspases
(A) Human Jurkat cell extracts, untreated or treated with cytochrome c and dATP to activate caspases,
were incubated at 37 °C for the indicated times.  Samples were electrophoresed on 12 % SDS-PAGE gels
and analysed by immunoblotting for isoforms of human 14-3-3 proteins and caspase-2.
(B-C) 35S-Methionine-labelled β-tubulin (B) and calreticulin (C) were incubated in Jurkat cell extracts
treated as above for the indicated times, followed by electrophoresis on 12 % SDS-PAGE gels.  Extract
samples were also analysed by immunoblotting as above to detect β−tubulin, calreticulin (polyclonal
antibody), and caspase-3.
(D) Lysates were prepared from CEM cells treated for 12 h with the indicated drugs.  Proteins were
resolved by SDS-PAGE and substrate cleavage assessed by Western blotting (calreticulin monoclonal
antibody).
Figure 5.  Exposure of calreticulin on the dying cell surface is dependent upon caspase activity
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11
(A) CEM cells were treated with actinomycin D (20 µM), DCI (100 µM), or VP-16 (100 µM) followed
by staining with Annexin V or immunostaining with anti-calreticulin antibodies.  Representative FACS
plots are shown.
(B) CEM.neo cells were incubated for 12 h in the presence of 20 µM actinomycin D with or without
50 µM z-VAD-fmk, followed by staining with annexin V and surface immunostaining with anti-
calreticulin. Representative FACS plots are shown.
(C) CEM.neo and CEM.Bcl-2 cells were incubated with 20 µM actinomycin D for 12 h followed by
surface immunostaining with anti-calreticulin.  Representative FACS plots are shown.
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Table I
Substrate Cleavage site
P4 P3 P2 P1 P1’
CED-3 N F V D220 A
D S V D374 G
D N R D388 G
CED-9 D A Q D47 L
E S I D67 G
CRT-1 V K I D182 G
D A E D225 A
D E M D253 G
TBB-2 E G M D404 E
N M N D417 L
D D V D435 G
FTT-2 D D T D240 A
Consensus D X X D G
Alignment of CED-3 cleavage sites
Sites of CED-3-mediated cleavage identified by site-directed mutagenesis in FTT-2, TBB-2 and
CRT-1 were aligned with known CED-3 cleavage sites in CED-3 and CED-9.  This alignment was
used to derive a consensus sequence for CED-3-mediated protein cleavage motifs.
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Figure 2
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A B
Figure 3
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Figure 4
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